+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Sleep Apnea Devices Market is anticipated to grow on account of rising geriatric population, increased awareness, growing pool of undiagnosed sleep apnea patients and growing disease diagnosis rates”, says Visiongain report

05 September 2019

Visiongain has launched a new pharma report Sleep Apnea Devices Market Report 2019-2029: By Diagnostic Devices (Polysomnography Devices (PSG), Pulse Oximeters, Actigraphy Devices), by Therapeutic Devices (Positive Airway Pressure (PAP) Devices, Oxygen Devices, Oral Appliances, Adaptive Servo Ventilation (ASV) Devices, Masks and Accessories) and Geography.

Global Sleep Apnea Devices Market is anticipated to grow on account of rising geriatric population, increased awareness, growing pool of undiagnosed sleep apnea patients and growing disease diagnosis rates. The global sleep apnea devices market is anticipated to grow at a lucrative CAGR of 6.7% and anticipated to reach USD 9.27 Billion by 2029.

Sleep apnea is a severe sleep disorder that happens when the breathing of a person during sleep is disrupted. People with untreated sleep apnea stop breathing constantly during their sleep.

The most prevalent type of apnea induced by airway blockage is obstructive sleep apnea. Patients must undergo diagnostic exams and use therapeutic therapy equipment to prevent this. In a sleep center or a home sleep apnea test, OSA is most frequently diagnosed with either polysomnography (PSG). OSA risk factors include obesity, aging, family history, and abnormalities of the facial or upper airways.  

Demand for OSA diagnosis and therapy has seen a fast rise in recent years, caused by exponential development in sleep apnea incidence, increased awareness, reimbursement accessibility, and increased patient adherence. According to the OHE-Office of Health Economics, OSA diagnosis, awareness and therapy can save up to USD 31 million of Nation Health Service. It is also noted that if everyone with mild to serious OSA were handled, it would be possible to prevent approximately 40,000 road accidents each year. Also rising number of OSA cases coupled with growing awareness about various treatments options is fueling the growth of the global market.

North America maintains a majority share of the market, and growth is ascribed to increased incidence of sleep disorders and increased government and non-governmental organizations initiatives to raise awareness of sleep disorders and sleep hygiene. Several government agencies run awareness programs to educate individuals and doctors about good sleeping habits. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the development of healthcare infrastructure in this region, combined with increased awareness among the population regarding associated risks of sleep apnea.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market. For instance, ResMed (US) introduced its first top-of-head nasal CPAP mask, AirFit N30i, across the US in 2019, with a freshly constructed nasal cradle cushion that sits just below the wearer's nose.

The comprehensive market report features companies such as Airing, Apnex Medical, BMC Medical, Braebon Medical, Carefusion Corporation, Compumedics, Contec Medical, Curative Medical Inc., Drive Devilbiss Healthcare, Fisher & Paykel Healthcare, Huanan Medical, Inspire Medical Systems, Invacare Corporation, Invicta Medical, Inc., Itamar Medical Ltd., Koninklijke Philips N.V., Löwenstein Medical, Medtronic, Natus Medical, Inc., Nihon Kohden, Nonin Medical, Novasom, Nukute, Nyxoah, Oventus, ResMed, Sefam, SomnoMed, Weinmann Medical Devices GmbH, and Whole You among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2022-2032

The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.

29 September 2022


Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022


Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022


Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022